EPElizabeth Price

Elizabeth Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Price has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes

    by Mark D Russell, Chun J Chan, Aran Sasitharan, Victoria Allen, Mark Gibson, Maryam A Adas, Samantha Goodliffe, Katie Bechman, Andrew P Cope, Sam Norton, et al.

    Objectives: To evaluate initial therapy with biologic and targeted synthetic DMARDs (b/tsDMARDs), compared with methotrexate, in patients with early RA. Methods: We systematically reviewed and meta-analysed randomized-controlled trials comparing initial b/tsDMARDs, combined with methotrexate or as monotherapy, against methotrexate in methotrexate-naïve adults with early RA. Pairwise and network meta-analysis were performed to compare DAS28 remission attainment, with the primary analysis at 6 months and secondary analyses at 3 and 12 months. Secondary outcomes included ACR50 response and CDAI remission. Results: Twenty-nine trials (13 387 participants) were included. Compared with methotrexate alone, initial b/tsDMARDs plus methotrexate significantly increased DAS28 remission at 6 months (risk ratio [RR] 1.62; 95% CI: 1.39, 1.89), 3 months (RR 1.95; 1.47, 2.57) and 12 months (RR 1.54; 1.39, 1.71), with benefits also observed for CDAI remission and ACR50 response. In network meta-analysis, all b/tsDMARD classes combined with methotrexate had higher remission rates than methotrexate alone. The benefits of b/tsDMARDs plus methotrexate were greater in studies with higher baseline disease activity and a greater proportion of rheumatoid factor-positive participants. As monotherapy, b/tsDMARDs increased DAS28 remission attainment compared with methotrexate at 6 months (RR 1.81; 1.42, 2.31), 3 months (RR 1.92; 1.31, 2.83) and 12 months (RR 1.46; 1.25, 1.71); however, at individual class level, significantly higher remission rates were observed only with tocilizumab and Janus kinase (JAK) inhibitor monotherapy. Conclusion: Initial therapy with b/tsDMARDs in combination with methotrexate is associated with higher remission rates than methotrexate alone in patients with early RA. As monotherapy, higher remission rates were observed for JAK inhibitors and tocilizumab.

  • Open Access

    Practical Guide to the Local Treatment of Sjogren’s Disease

    by Elizabeth J. Price, Shirleen Hallang, Guy Smith

    Dryness (sicca) of mucosal surfaces is the hallmark of adult-onset Sjogren’s disease (SjD). In our experience, clinicians frequently lack confidence in managing the sicca symptoms effectively. Successful management requires an understanding of the condition and personalisation of care. We have reviewed the available evidence and, when necessary, used personal and expert experience to provide comprehensive advice on the management of ocular, oral, and systemic sicca, enabling the treating physician to support their patients and manage their symptoms effectively and prevent long-term damage. Our objective is to ensure that the non-specialist feels confident in managing the myriad manifestations of sicca in SjD.


  • Open Access

    Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK

    by Zijing Yang, Fabiola Atzeni, Mark Russell, Kaiyang Song, Callum Coalwood, Elizabeth Price, Maya Buch, Sam Norton, James Galloway

    Objective: Patients with inflammatory arthritis (IA), including RA and PsA, have an elevated cardiovascular disease (CVD) risk. It is unclear whether this persists in the modern treat-to-target era, particularly in early disease. This study evaluates CVD risk and mortality in a contemporary early RA and PsA cohort. Methods: Adults (≥18 years) with newly diagnosed RA or PsA registered in the National Early Inflammatory Arthritis Audit (NEIAA) from 2018 to 2023 were included. Incidence rates of CVD events, major adverse cardiovascular events (MACE) and all-cause and CVD mortality were calculated. Standardized incidence and mortality ratios compared outcomes with the general population. Competing risk regression assessed factors associated with CVD outcomes. Results: A total of 1012/17 669 RA and 104/3271 PsA participants had CVD hospitalizations. The incidence of MACE hospitalizations was 2.4/100 person-years (95% CI 2.2, 2.7) in RA and 0.6/100 person-years (95% CI 0.4, 1.0) in PsA. The risk of CVD hospitalizations was ≈25% higher in IA participants. Compared with the general population, all-cause mortality was 1.1 times higher in RA. CVD incidence and mortality were consistently higher in males. Hypertension, diabetes and smoking were associated with an increased CVD risk. Early corticosteroid use did not predict CVD, while better early RA treatment response was linked to lower CVD risk. Conclusion: A greater incidence of CVD and MACE exists in early IA, although less than previously reported. Traditional CVD risk factors are the dominant explanation for the risk increase, with disease control being a smaller but significant contributor to risk. Routine cardiovascular risk assessment in early IA remains justified.


  • Open Access

    Development of a clinical tool to identify patients with early inflammatory arthritis at high risk of employment loss: analysis from the National Early Inflammatory Arthritis Audit

    by Ed Alveyn, Katie Bechman, Maryam Adas, Paul Amlani-Hatcher, Mini Dey, Sarah Gallagher, Mark Gibson, Bethan Jones, Daksh Mehta, Sam Norton, et al.

    Objectives: Work disability is an early consequence of inflammatory arthritis. Preventive interventions exist but access is limited, highlighting the need for risk stratification. We aimed to develop a tool using routinely collected data to identify patients at greatest risk of employment loss. Methods: This cohort study used data from the National Early Inflammatory Arthritis Audit. Patients ≥16 years with early inflammatory arthritis (EIA), enrolled May 2018–April 2025, employed at diagnosis and with three-month follow-up were included. The outcome was self-reported employment loss at 3 months. Predictors were occupation (manual vs non-manual), age, sex, disease activity (DAS28 > 5.1), mental health (anxiety/depression) and musculoskeletal burden (MSKHQ ≤25v > 25). Employment loss was modelled using Poisson regression. Model discrimination, calibration and bootstrap validation were assessed. A risk score was derived and stratified into low, medium and high-risk groups. Results: Of 11 894 patients with EIA, 6036 were employed at baseline and 1662 had complete work-outcome data. At 3 months, 168(10.1%) reported employment loss. Manual workers had higher risk than non-manual (14.1% vs 7.8%). In multivariable analysis, manual work (IRR: 1.54, 95% CI: 1.15–2.06), older age (per 10 years: IRR: 1.65, 95% CI: 1.43–1.90), high musculoskeletal burden (IRR: 1.55, 1.10–2.19) and anxiety/depression (IRR: 1.45, 1.02–2.06) were associated with employment loss, whereas DAS28 was not. The optimal model (age, occupation, musculoskeletal and mental health) showed good discrimination (C-statistic 0.710) and calibration. An 8-point score stratified patients into low (2.5%), medium (9.1%) and high-risk (19.5%). Conclusion: Employment loss in EIA is driven by occupation, age, musculoskeletal symptoms and mental health. A risk tool incorporating these domains can stratify patients and guide targeted interventions.


  • Open Access

    Time trends in new diagnoses of 19 long-term conditions: a population-level cohort study in England using OpenSAFELY

    by Mark D Russell, Andrea L Schaffer, Katie Bechman, Mark Gibson, Jon Massey, Rose Higgins, Brian MacKenna, Peter Inglesby, Seb Bacon, Amir Mehrkar, et al.

    Objectives: To evaluate temporal changes in the incidence and prevalence of 19 long-term conditions in England, quantifying the impact of the COVID-19 pandemic on diagnosis rates by disease, age group, sex, socioeconomic status, and ethnicity. Design: Observational cohort study. Setting: Primary care and hospital admission data, with the approval of NHS England. Participants: 27,132,190 individuals registered with general practices in England contributing data to the OpenSAFELY-TPP platform. Main outcomes measures: Temporal trends in age and sex-standardised incidence and prevalence were evaluated for 19 long-term conditions between April 1, 2016, and November 30, 2024. Differences between expected and observed incidence rates after the onset of the COVID-19 pandemic were compared using seasonal autoregressive integrated moving-average models. Results: Between March 2020 and November 2024, persistent large deficits in incident diagnoses were evident for depression (738,068 [28.0%] fewer diagnoses than expected; 95% CI 701,452 to 774,685), asthma (150,708 [16.0%] fewer diagnoses; 95% CI 133,300 to 168,117), COPD (84,084 [15.1%] fewer diagnoses; 95% CI 74,342 to 93,827), osteoporosis (78,891 [16.5%] fewer diagnoses; 95% CI 72,804 to 84,978) and psoriasis (56,231 [17.6%] fewer diagnoses; 95% CI 51,054 to 61,407). Conversely, post-pandemic diagnoses of chronic kidney disease (CKD) have increased by 32.7% above expected levels, corresponding to 325,996 additional diagnoses (95% CI 252,212 to 399,779). Dementia diagnoses have rebounded above pre-pandemic levels for individuals of White ethnicity and less deprived socioeconomic quintiles, but remain lower than expected for individuals from other ethnicities and more deprived communities. Conclusions: There has been a lasting and disproportionate impact of the pandemic on conditions including depression, asthma, COPD and osteoporosis, contrasting a post-pandemic surge in CKD diagnoses. Analyses stratified by ethnicity and socioeconomic status reveal inequity in the recovery from the pandemic, particularly for individuals with dementia. Importantly, this study demonstrates the potential for near real-time monitoring of disease epidemiology using routinely collected health data, informing strategies to enhance case detection and address healthcare disparities. Summary box: What is already known: Early in the COVID-19 pandemic, large deficits in newly-recorded diagnoses were reported for a range of long-term conditions, including chronic obstructive pulmonary disease (COPD), depression, asthma and rheumatoid arthritis. However, no population-level studies have evaluated whether diagnosis rates have subsequently recovered as healthcare services emerge from the pandemic, or compared the impact by disease, age group, sex, socioeconomic status, and ethnicity. What this study adds: Large deficits in diagnoses remain evident for conditions including depression, COPD, asthma, osteoporosis and psoriasis, contrasting a surge in new diagnoses of chronic kidney disease since 2022. Diagnosis rates for dementia have reached pre-pandemic levels for individuals of White ethnicity and those from less deprived socioeconomic communities, but remain lower than expected among individuals from other ethnicities and more deprived communities. This study demonstrates how routinely collected health data can transform monitoring of disease epidemiology in near real-time and highlight healthcare inequity.

  • Open Access

    Risk of infection in patients with early inflammatory arthritis: results from a large UK prospective observational cohort study

    by Maryam A Adas, Katie Bechman, Mark D Russell, Victoria Allen, Samir Patel, Mark Gibson, Ioasaf Karafotias, Kathryn Biddle, Benjamin Zuckerman, Kaiyang Song, et al.

    Objective: To identify risk of serious infections (SI) according to initial conventional synthetic DMARDs (csDMARD) and CS, in patients recruited to the National Early Inflammatory Arthritis Audit. Methods: An observational cohort study was used, including adults in England and Wales with new diagnoses of RA between 2018 and 2023. The main outcome was SI events, defined as infections requiring hospitalization/or resulting in death. Secondary analyses evaluated SI-related mortality alone. Hazard ratios (HR) were calculated using cox proportional hazards models. Primary predictor was initial treatment strategy, with confounder adjustments. Results: A total of 17 472 patients were included, of whom 10 997 were on MTX-based strategies, 4540 on other csDMARDs and 13 680 received CS. There were 1307 SI events, corresponding to incidence rates (IR) per 100 person-years of 3.02 (95% CI 2.86–3.19) and 311 cases of SI-related mortality (IR 0.69, 95% CI 0.61–0.77). MTX-based strategies were associated with reduced risk of SI events compared with other csDMARDs (adjusted HR 0.72, 95% CI 0.63–0.82). In unadjusted models, CS was associated with higher risk of SI events, but in adjusted models this association was no longer significant (adjusted HR 0.99, 95% CI 0.87–1.12). Increasing age, being a current/or ex-smoker (relative to non-smoker), having a comorbidity, being seropositive and having high DAS based on 28 joint count (DAS28) were all associated with increased incidence of SI. One unit increase in baseline DAS28 increases the risk of SI event by 10%. Conclusion: MTX-based regimens associated with a reduced risk of SI compared with other strategies. Patient-level and disease-related factors at diagnosis are important predictors of SI in individuals with new RA.


  • Open Access

    Trends in remission rates for rheumatoid arthritis in England and Wales: a population-level cohort study

    by Edward Alveyn, Callum Coalwood, Gráinne Farrell, Ella Jackson, Maryam A Adas, Sam Norton, Peter Lanyon, Elizabeth Price, Joanna M Ledingham, James B Galloway, et al.

    Objectives: Considerable data support early treatment of RA to obtain disease remission. Data from the National Early Inflammatory Arthritis Audit (NEIAA) in England and Wales suggest that, despite recent improvements in referral-to-treatment times, remission rates remain unchanged. We investigated reasons for this disconnect by evaluating temporal trends, geographical variation and predictors of remission in individuals with new RA diagnoses. Methods: An observational cohort study of individuals with RA was conducted using data from NEIAA (May 2018–April 2024). Temporal and geographical variation in remission rates (DAS28 < 2.6) were explored using interrupted time-series and case-mix-adjusted mixed-effects regression. Predictors of remission were assessed using multivariable logistic regression. Results: 13 752 of 21 904 (62.8%) individuals with RA had data on DAS28 at 3 months after initial rheumatology assessment, of whom 4764 (34.6%) achieved remission. National remission rates were stable from 2018 to 2024; however, wide geographical variation was observed, ranging from 28.4% (London) to 40.3% (East of England). Threefold differences in remission rates were seen between individual hospitals within regions. Younger age, female sex, Black ethnicity, higher baseline DAS28, delayed DMARD initiation and longer symptom duration were independently associated with reduced odds of remission. Delays between symptom onset and referral have increased since the COVID-19 pandemic. Conclusion: While national remission rates for early RA have remained stable in England and Wales since 2018, there is marked regional and hospital-level variation, highlighting ongoing inequities in service delivery. Addressing factors beyond referral-to-treatment time—particularly delayed presentation to primary care—is required to improve remission rates.


  • Open Access

    Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study

    by Zijing Yang, Edward Alveyn, Mark Russell, Katie Bechman, Callum Coalwood, Elizabeth Price, Abhishek Abhishek, Sam Norton, James Galloway

    Objectives: To update the first-line conventional synthetic DMARDs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the RA population, and identify individual and hospital factors associated with it. Methods: This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018 to 1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering. Results: We identified 15 462 RA patients who received csDMARD treatment. Overall, 57% received MTX monotherapy and 14% received MTX combination therapy as first-line treatment. MTX is the most frequently medication, following by HCQ and SSZ. Compared with non-MTX prescription, prescription of MTX monotherapy [adjusted odds ratio (aOR) 1.25 95% CI (1.22–1.29)] and MTX combination therapy [aOR 1.45 (1.38–1.52)] was significantly higher in patients with higher DAS28, but lower in the non-White individuals with comorbidities: lung disease, cancer, fracture and heart attack. Among those who received MTX, monotherapy is more likely be prescribed in patients with higher DAS28 [aOR 1.08 (1.05–1.11)] and without lung disease [aOR 0.5 (0.44–0.56)], compared with combination therapy. Around 20% of the variability in first-line csDMARD prescribing was attributed to the hospital level. Conclusion: In this cohort study of new-onset RA population, both individual- and institution-level variation in first-line csDMARD treatment strategy was evident. Gender, ethnicity, disease activity, and comorbidities, especially lung disease, were associated with disparities at the individual level.


  • Open Access

    Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study

    by Mark D Russell, Zijing Yang, Niamh Dooley, Mark Gibson, Benjamin Zuckerman, Maryam A Adas, Edward Alveyn, Samir Patel, Katie Bechman, Elizabeth Price, et al.

    Objective: The objective of this study was to evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for RA in England and Wales. Methods: An observational cohort study was conducted for people with RA enrolled in the National Early Inflammatory Arthritis Audit (NEIAA) between May 2018 and April 2022 who had 12-month follow-up data available. Temporal trends in escalation to b/tsDMARDs within 12 months of initial rheumatology assessment were explored, including comparisons before and after publication (July 2021) of national guidelines that lowered the threshold for b/tsDMARD initiation to include moderate-severity RA. Case-mix–adjusted, mixed-effects regression was used to evaluate regional and hospital-level variation in b/tsDMARD initiation. Results: Of 6098 RA patients with available follow-up, 508 (8.3%) initiated b/tsDMARDs within 12 months of initial assessment. b/tsDMARD escalation increased marginally towards the end of the study period (9.2% in May 2021/22); however, no significant differences were evident after guidelines were published permitting b/tsDMARD use for moderate-severity RA. The proportion of individuals escalated to b/tsDMARDs varied considerably between regions, ranging from 5.1% in Wales to 10.7% in North-West England. Following case-mix adjustment, the intraclass correlation (ICC) for hospitals within regions was 0.17, compared with a between-region ICC of 0.0, suggesting that the observable regional variation reflected hospital-level differences rather than systematic differences between regions themselves. Conclusion: There is marked variation in escalation to b/tsDMARDs for people newly diagnosed with RA throughout England and Wales, despite a universal health-care system. These disparities must be addressed if we are to deliver equitable access to b/tsDMARDs, regardless of geography.


  • Open Access

    Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

    by Elizabeth J Price, Stuart Benjamin, Michele Bombardieri, Simon Bowman, Sara Carty, Coziana Ciurtin, Bridget Crampton, Annabel Dawson, Benjamin A Fisher, Ian Giles, et al.